Cardio Diagnostics Holdings, Inc. (NASDAQ: CDIO) CEO and Co-Founder Dr. Meesha Dogan recently appeared on The BioMedWire Podcast to discuss the company’s mission to improve cardiovascular disease prevention and early detection through precision medicine powered by epigenetics, genetics, and artificial intelligence. The interview highlighted key strategic initiatives, including the company’s expansion into India and progress through the Medicare reimbursement process.
Dr. Dogan emphasized that Cardio Diagnostics leverages a proprietary Artificial Intelligence-driven Integrated Genetic-Epigenetic Engine, or Core Technology, to make cardiovascular disease prevention, detection, and management more accessible, personalized, and precise. The company aims to become a leading medical technology company for improving prevention, detection, and treatment of cardiovascular disease.
A significant portion of the discussion focused on Cardio Diagnostics’ expansion into India through partnerships with Aimil Ltd. and Dr. Lal PathLabs. These collaborations are expected to extend the company’s reach into one of the world’s most populous markets, where cardiovascular disease is a leading cause of death. The partnerships will enable the distribution and use of Cardio Diagnostics’ tests in India, potentially impacting millions of patients.
Regarding the Medicare reimbursement process, Dr. Dogan noted that the CPT coding and payment steps have been completed, which are critical for establishing billing and coverage. However, the coverage determination remains underway. This progress is essential for making the company’s tests accessible to Medicare beneficiaries, a large segment of the U.S. population at risk for cardiovascular disease.
The implications of these developments are significant for the healthcare industry and investors. For patients, Cardio Diagnostics’ precision medicine approach could lead to earlier detection and personalized treatment plans, potentially reducing mortality and healthcare costs. For the industry, the company’s AI-driven tests represent a shift toward more data-driven cardiovascular care. The India expansion opens a massive new market, while Medicare coverage would provide a stable revenue stream and validate the clinical utility of the tests.
Cardio Diagnostics’ newsroom, which provides updates on the company, is available at https://ibn.fm/CDIO. The full press release about the podcast can be accessed at https://ibn.fm/0VjIz.
Cardio Diagnostics is an artificial intelligence-powered precision cardiovascular medicine company. The company was formed to further develop and commercialize clinical tests by leveraging its proprietary AI-driven Core Technology. BioMedWire, which hosted the podcast, is a specialized communications platform focusing on biotechnology, biomedical sciences, and life sciences, and is one of over 75 brands within the Dynamic Brand Portfolio @IBN.
